Navigation Links
Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
Date:8/28/2007

HAMBURG, Germany and OXFORD, England, August 28 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) is pleased to invite you to a webcast presentation and conference call on detailed Phase II data for its lead compound EVT 201 in the treatment of insomnia on 5 September 2007 at 11.00 am CET / 10.00 am GMT / 5.00 am EST / 7.00 pm AEST

The Evotec speakers at the worldsleep07 congress and in the webcast and conference call will be:

- Dr John Kemp, Chief Research and Development Officer

- Dr Tim Tasker, Executive Vice President Clinical Development

Evotec will host a poster presentation on the study results at the worldsleep07 congress from 4.00 to 6.00 pm AEST time at the Sofitel Reef Hotel, 35-41 Wharf Street, Cairns, Australia (poster No PO649). Following the conference presentation, Evotec will hold the webcast and conference call to discuss the results. Positive headline results of this first Phase II study in 67 patients were released on 4 June 2007.

To attend the webcast and conference call, please dial in using the following phone numbers:

Australia +61-(2)-8223-9234

Germany +49-(69)-9897-2631

Switzerland +41-(44)-800-9659

UK +44-(20)-7138-0814

USA +1-(718)-354-1157

PIN code: 5301349

Please dial in 10 minutes before the beginning of the conference.

The presentation will be available at the Evotec homepage http://www.evotec.com.

Evotec expects the results from a second Phase II study in 135 elderly insomniacs to be available in October 2007.

Although certain aspects of insomnia are addressed by current treatments, there is no drug yet available which meets all the needs of insomnia patients.

About EVT 201

EVT 201 is a partial positive allosteric modulator (pPAM) of the GABAA receptor complex. Acting on GABAA receptors it addresses the gold standard mechanism for insomnia with more than 90% of current insomnia drugs using this mechanism. Importantly, however, its close to ideal half life of 3 to 4 hours and its partial agonist activity gives EVT 201 a differentiated preclinical profile and mechanism of action.

The headline results of the first Phase II study with EVT 201 were very positive in terms of all aspects of the problems faced by insomniacs, i.e. sleep onset and sleep maintenance and yet the patients didn't feel any drug hang-over effects after waking in the morning. Furthermore, in two previous Phase I/II proof-of-principle studies in subjects with induced insomnia, EVT 201 significantly reduced Wake After Sleep Onset (WASO) while significantly increasing the Total Sleep Time (TST) and quality of sleep with no subjective residual effects. The studies were conducted in a sleep laboratory setting using the traffic noise model of insomnia in healthy male volunteers. In this setting an average of 52 decibels of recorded traffic noise is played throughout the night thereby provoking insomnia. This model has been used to evaluate several insomnia treatments currently in development and on the market. EVT 201 showed no tolerance/dependence liabilities in pre-clinical studies and no interaction with alcohol.

Joern Aldag

President & Chief Executive Office

T: +49-(0)40-560-81-242

F: +49-(0)40-560-81-333

joern.aldag@evotec.com

Anne Hennecke

Senior Vice President

Investor Relations & Corporate Communications

T: +49-(0)40-560-81-286

F: +49-(0)40-560-81-333

anne.hennecke@evotec.com

Evotec AG (Headquarters)

Schnackenburgallee 114

22525 Hamburg, Germany


'/>"/>
SOURCE Evotec AG
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... 21, 2017 , ... Finalists have recently been selected for ... have implemented innovative products, services, and technology over the past year. The innovations ... and market need. The applicants with the top three scores in each category ...
(Date:8/18/2017)... ... 2017 , ... Producers of the award winning American Farmer ... upcoming episode, scheduled to broadcast fourth quarter 2017. American Farmer airs Tuesdays at ... family-owned seed company. Educating audiences about its broad portfolio of products to help ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... Electrospraying line of nanofiber and nanoparticle fabrication instruments from Bioinicia. ... to fully automated pilot plants and equipment for industrial manufacturing. All equipment ...
(Date:8/16/2017)... of the Inc. 5000 features a now-familiar name: BioPoint ( http://biopointinc.com/ ), ... for the third year in a row. Now in its 36th edition, ... set of quantitative metrics. In addition, BioPoint was also named to the ... Bay State . ... ...
Breaking Biology Technology:
(Date:4/13/2017)... , April 13, 2017 According to a new ... Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, ... IAM Market is expected to grow from USD 14.30 Billion in 2017 ... (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
Breaking Biology News(10 mins):